Olopatadin Orifarm (Olopatadine)

Olopatadine is indicated for allergic eye conditions that involve histamine‑mediated inflammation.

• Allergic conjunctivitis: Reduces redness, itching and swelling of the eyes.
• Seasonal allergic rhinoconjunctivitis: Alleviates combined nasal and ocular allergy symptoms.
• Vernal keratoconjunctivitis: Helps control chronic inflammation of the cornea and conjunctiva.
• Atopic keratoconjunctivitis: Provides relief for persistent ocular itching and discomfort.
• Contact lens‑related allergy: Decreases irritation for lens wearers with allergic responses.

• Olopatadine acts as a selective antagonist of the histamine H1 receptor, blocking the action of histamine released during allergic reactions. It also exhibits mast‑cell stabilising properties, preventing further release of inflammatory mediators such as leukotrienes and prostagoleins. This dual action reduces ocular itching, redness and swelling associated with allergic eye disease.

Olopatadine is generally well‑tolerated, but some patients may experience adverse reactions.

Common Side Effects

• Burning sensation in the eye
• Blurred vision
• Headache
• Dry eye
• Mild ocular irritation
• Unpleasant taste (if oral formulation)

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis)
• Significant eye pain or vision loss
• Persistent swelling of the eyelids
• Corneal ulceration
• Stevens‑Johnson syndrome
• Acute angle‑closure glaucoma

When using Olopatadin Orifarm, consider the following safety measures:

• Assess allergy history: Verify patient has no known hypersensitivity to olopatadine or similar antihistamines.
• Monitor ocular health: Regular eye examinations are recommended during prolonged use.
• Caution in glaucoma patients: Use with care in individuals with narrow‑angle glaucoma.
• Pregnancy and lactation: Discuss risks and benefits with a healthcare professional before use.
• Drug interactions: Review concomitant medications for potential additive antihistamine effects.
• Store at ambient temperature: Keep below 25°C, in the original packaging, protected from moisture and light.

Olopatadine may interact with other medications that influence histamine pathways or cause additive sedation. Major Interactions (Avoid):\n- Monoamine oxidase inhibitors (MAOIs): Increased risk of hypertensive reactions.

• Tricyclic antidepressants: Potential for enhanced anticholinergic effects.

Moderate Interactions (Monitor Closely)

• Other antihistamines: May increase sedation or dry‑mouth effects.
• Sedative CNS depressants: Possible additive drowsiness.
• Anticholinergic drugs: May exacerbate dry‑eye symptoms.
• Beta‑blocker eye drops: Potential reduction in intra‑ocular pressure control.
• Systemic corticosteroids: May alter ocular healing response.